Director

John F. Milligan, Ph.D.

Director and Executive Chairman·4D Molecular Therapeutics, Inc.

About

Executive Chairman of the board since August 2020. Former President and CEO of Gilead Sciences (2016-2019) after 29 years at Gilead. Serves on the boards of Pacific Biosciences of California and Kailera Therapeutics.

Since 2020
Tenure 6 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director SM Shawn Cline Tomasello, MBA Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Director and Executive Chairman 2020–present Current role

Related

Company 4D Molecular Therapeutics, Inc. Company hub Person David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director Person Jacob Chacko, M.D., MBA Director Person Susannah Gray, MBA Director Person Charles P. Theuer, M.D., Ph.D. Director Person Nancy Miller-Rich Director Person Shawn Cline Tomasello, MBA Director Person Glenn Sblendorio Director Person Kristian Humer Chief Financial Officer Person Christopher Simms Chief Commercial and Business Officer Person Scott Bizily, J.D., Ph.D. Chief Legal Officer and Corporate Secretary Person Ashoo Gupta Vice President, Finance and Controller Person Fariborz Kamal, Ph.D. Former President and Chief Operating Officer; Chief Technical Advisor
Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo